ArticleACS omega2026

Repurposing Masitinib Mesylate as a Novel FOXM1 Inhibitor for the Treatment of Aggressive Solid Tumors: Preclinical Validation in Human Breast and Oral Cancer Cells and Organotypic Tumor Slice Culture.

Rajat Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.